Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ixekizumab (Taltz®) cannot be endorsed for use within NHS Wales for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy. |
||
|
||
Medicine details |
||
| Medicine name | ixekizumab (Taltz®) | |
| Formulation | 80 mg solution for injection | |
| Reference number | 4398 | |
| Indication | Treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Skin | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 23/07/2021 | |